Contract
Marketing Manager
Peripheral Interventions, Month Fixed Term Contract, Marketing, Marketing
Posted on 10/30/2025
Boston Scientific
10,001+ employees
Medical devices maker for interventional specialties
No salary listed
Brisbane QLD, Australia + 2 more
More locations: Melbourne VIC, Australia | Sydney NSW, Australia
In Person
 Growth & Marketing (3) |
|---|
| , , |
- Bachelor’s degree in Marketing, Business, Life Sciences or related field
- Previous demonstrated experience in a Senior Product or Marketing Manager role, preferably within the medical devices industry
- Proven success in digital marketing strategy and execution, with CRM and automation platform experience
- Demonstrated success launching new products and managing full-cycle campaigns
- Commercial acumen and ability to translate market insights into actionable plans
- Excellent stakeholder management and communication skills
- Data-driven and performance-focused, with strong analytical skills
- Adaptable, collaborative and results-oriented
- Strategic thinker with a hands-on approach to execution
- Develop strategic marketing plans centred around the PI/ Interventional Oncology (IO) product portfolio
- Work with Business Unit Director to complete annual strategic and operating plans. Working closely with the Business Unit Director and FP&A Analyst to develop cohesive and credible plans is a central part of this responsibility
- Identify gaps and opportunities in referral pathways and create initiatives to support healthcare professionals
- Collaborate cross-functionally with clinical, sales, and medical affairs teams to ensure alignment with treatment pathways
- Responsible for developing a high performing team and facilitating a positive winning spirit and collaborative culture. You effectively partner with other stakeholders internally and externally to enhance your impact. Ensure the Peripheral Interventions marketing team receive ongoing regular feedback, training and help in identifying, supporting and achieving agreed upon performance/business objectives. Support employees in their career development through coaching and mentoring, helping them set and achieve development objectives and professional goals
- Plan and execute new product launches and strategies that set Boston Scientific products apart from the competition, provide good market fit and produce profitable growth. Positive collaboration with internal functions to ensure each part of the plan is progressing as intended are an essential part of this responsibility as well as managing time in the field to ensure messaging and positioning has the intended impact
- Create and execute initiatives that continue to build the Boston Scientific brand with ANZ physicians and related stakeholders. Managing branding and activities at major ANZ specialty conferences, as well as local Boston Scientific sponsored events, will be key activities in this responsibility
- Ensuring marketing collaterals and materials are compliant with Boston Scientific brand standards and guidelines
- Compliant collaboration with international and local key customers to assist you with execution of training and education programs, conducting product evaluations and providing local strategic and clinical guidance are key parts of this responsibility
- Research and execute public and private pricing strategies that represent maximum value for all stakeholders. Collaborating with Health Economics and Government Affairs functions to obtain timely and commensurate reimbursement is key to this responsibility
- Identify and/or create new market opportunities across ANZ. Spending a high percentage of time in the field with Territory Managers is critical to successfully managing this responsibility
- Implement strategies to facilitate feedback from the field team to marketing. Play a lead role in developing plans and internal communications for the field team including product launch materials, materials supporting strategic areas of focus, quarterly plan of action and product updates
- As a senior leader, demonstrate the ability to lead without direct influence, aligning the sales organization to the key marketing pillars. Collaborate with RSM’s to execute strategy
- Hands on in the product lifecycle management, including demand forecasting and coordination with operations to optimize service levels and minimize excess inventory. Working with the Product Manager and Marketing Associate to localise and update marketing materials is also essential
Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.
Company Size
10,001+
Company Stage
IPO
Headquarters
Marlborough, Massachusetts
Founded
1979
Simplify's Take
What believers are saying
- Pending Penumbra acquisition adds $374.8M Q1 2026 thrombectomy revenue and 15.6% growth.
- €75M Galway R&D expansion targets cardiovascular, heart failure, and renal denervation innovations.
- Cardiovascular segment delivers $3.5B Q1 2026 revenue with 13.5% year-over-year increase.
What critics are saying
- Polen Capital sells stake citing electrophysiology competition from Medtronic and Abbott erodes share.
- 2026 securities-fraud class action over Electrophysiology growth triggers settlement by mid-2027.
- Pelvic mesh litigation yields multi-billion judgment crippling urology by 2028.
What makes Boston Scientific unique
- FARAPULSE PFA platform superior to anti-arrhythmic drugs in AVANT GUARD trial at Heart Rhythm 2026.
- WATCHMAN franchise achieves 19% global growth in Q1 2026 structural heart procedures.
- Asurys Fluid Management System gains FDA clearance for real-time urologic pressure control.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Relocation Assistance
Performance Bonus
Company News
Boston Scientific announces €75 million investment to expand R&D capabilities in Galway. 15/04/2026 Ireland GALWAY, IRELAND (15 April 2026) - Boston Scientific Corporation (NYSE: BSX) - a global leader in medical device technology - today announced a €75 million investment in its Galway site, including the expansion of its research and development (R&D) capabilities, further strengthening its role as a global centre for cardiovascular innovation. The development, which is supported by funding from the Irish government through IDA Ireland, includes purpose-built laboratories to enhance the ability of teams in Galway to design, develop and test next-generation medical technologies across a range of cardiovascular therapies. The expanded capability will support priority programmes across structural heart, cardiovascular and endoscopy, as well as emerging areas such as heart failure and renal denervation technologies, underpinned by a strong regional talent base and STEM ecosystem. Regarding the announcement, Minister for Education and Youth, Hildegarde Naughton said: "The decision by Boston Scientific to invest again in Galway shows real confidence in the talent and infrastructure available here. The importance of R&D and innovation to Ireland's economy cannot be overstated. It is achieved through a strong partnership between industry, Government and IDA Ireland and has acknowledged that Galway is now an internationally recognised MedTech hub. This is due in no small part to the presence of Boston Scientific, one of the largest life sciences employers in the country, and I want to very much thank them for their continued investment." Minister for Enterprise, Tourism and Employment, Peter Burke said: "This €75 million investment by Boston Scientific is a strong vote of confidence in Galway, in Ireland's life sciences ecosystem, and in the highly skilled workforce that underpins it. Expanding R&D capability in this way strengthens Ireland's role as a global hub for medical technology innovation and supports the development of life changing treatments for patients worldwide. The Government is committed to supporting companies like Boston Scientific as they continue to scale, innovate and create high value employment across the regions." As a global leader in medical technology innovation, Boston Scientific continues to invest in capabilities that advance patient care, with Galway playing a key role in delivering that innovation. "We are seeing strong momentum across our cardiovascular business, and this investment reflects the important role the Galway site plays in that progress," said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies, Boston Scientific. "The local team is delivering complex, highly collaborative work that is advancing meaningful innovation for patients. The strength of the site, the talent in Ireland and the support of the Irish Government and IDA Ireland give us confidence to continue investing in our future growth." Boston Scientific has a long-established presence in Ireland spanning over 30 years, with over 7,000 employees across sites in Galway, Cork and Clonmel producing over 30 million devices each year for patients worldwide. Medical devices exported from the Galway facility every year include drug-coated devices, vascular balloons and heart and oesophageal stents. These products help treat patients with conditions including heart disease, vascular disease, oesophageal cancer and those at risk of stroke. Rachel Shelly, Global Head of Life Sciences at IDA Ireland, stated: "Boston Scientific's €75 million R&D investment in Galway reinforces Ireland's leadership in medical technology innovation. For more than 30 years, Boston Scientific has invested in advanced manufacturing and innovative technologies in Ireland, benefiting patients, communities and ecosystems locally and globally. IDA Ireland looks forward to continued collaboration with Boston Scientific to advance MedTech excellence." You might also be interested in. Klaviyo invests in engineering hub in Ireland. New senior engineering roles in Dublin put Irish talent at the centre of a platform delivering personalised customer experiences for 193,000 consumer brands worldwide Prove accelerates global innovation with expansion of Ireland R&D hub. $5M investment and expanded Dublin team accelerates product strategy and supports Prove's growing global customer base
Boston Scientific has raised $120 million in Series C funding at a $1.45 billion valuation, led by Ribbit Capital with participation from Sequoia, Kleiner Perkins and new backer Emerson Collective. The pre-revenue AI startup, co-founded by Robinhood CEO Vlad Tenev, is developing "Mathematical Superintelligence" to eliminate AI hallucinations through formal reasoning. Its Aristotle model requires outputs in Lean4 programming language, enabling verification for correctness. The model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, Boston Scientific has raised $295 million across three rounds in 14 months. The company offers Aristotle via free API and targets commercialisation in safety-critical sectors including aerospace, finance and automotive.
Boston Scientific presents Watchman FLX and EKOS endovascular system data. Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans. Boston Scientific has shared a duo of positive data readouts from two separate trials evaluating its Watchman FLX left atrial appendage closure (LAAC) device in non-valvular atrial fibrillation (AF) patients, and its EKOS endovascular system in patients with intermediate-risk pulmonary embolism (PE). The Watchman trial evaluated whether the device represented a reasonable alternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular AF, while the Ekos trial evaluated whether the endovascular system was superior to the current standard of care (SoC) - anticoagulation alone - in treating patients with acute PE. The results from each study were shared during the 2026 American College of Cardiology (ACC) conference, which took place from 28 to 30 March in New Orleans, Louisiana. The findings from each study were also simultaneously published in The New England Journal of Medicine. In the 3,000-patient CHAMPION-AF (NCT04394546) trial, Watchman met its primary safety endpoint as a first-line option for stroke risk reduction in patients with non-valvular AF. The device proved statistically superior to NOACs at the three-year readout, achieving a 45% relative reduction in non-procedural bleeding risk. The study's primary efficacy endpoint, defined as the occurrence of stroke, cardiovascular or unexplained death or systemic embolism, was met, with Watchman achieving statistical non-inferiority compared to NOACs at 5.7% versus 4.8%. Including procedural bleeding in a secondary analysis, Watchman was consistent with the primary safety endpoint and demonstrated a significant reduction in bleeding compared to NOACs, representing a 34% relative reduction in procedural and non-procedural bleeding risk. "These positive data, which have the potential to support updated clinical guidelines globally, will be used in our submission to expand the indication and coverage for the well-established Watchman platform as a first-line stroke risk reduction option, providing physicians with more choices in care for a wider range of patients who have atrial fibrillation," said Brad Sutton, chief medical officer, atrial fibrillation solutions at Boston Scientific. "Today, 40% of patients with AF who are prescribed blood thinners for stroke risk reduction are not taking their medications consistently, significantly increasing their risk of stroke," Sutton added. Boston's Watchman franchise represents a key revenue driver within the company's cardiovascular portfolio. In Q4 2025, the franchise achieved a 29.4% uptick on its Q4 2024 performance, contributing $535m to Boston's $3.4bn revenue performance in Q4 2025. In the 544-patient HI-PEITHO trial (NCT04790370), Boston's Ekos system's delivery of a low dose of clot-dissolving medication directly to the blood clot to facilitate the dispersion of the medication deep into the clot to dissolve it was compared against the SoC of anticoagulation alone. Meeting the trial's co-primary endpoint of PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse and non-fatal symptomatic recurrence of PE within seven days, Ekos plus anticoagulation demonstrated superiority to anticoagulation alone at 4% versus 10.3%, representing a 61% reduction in the primary endpoint events. This result was achieved with no episodes of bleeding within the brain through 30 days. Dr Michael Jaff, vice president and chief medical officer, vascular therapies at Boston Scientific, said: "The HI-PEITHO trial evaluated clear, clinically meaningful endpoints using rigorous patient enrolment criteria and demonstrated a definitive impact with the Ekos system over the standard of care for treating acute PE. "For the first time, we have robust randomised clinical trial data available to inform treatment decisions by interventionalists and referring physicians and support consideration of Ekos plus anticoagulation as a first-line therapy." Give your business an edge with its leading industry insights.
Nominations open for the second annual Thomas J. Fogarty Prize honoring high-impact medtech innovations. $100,000 Cash Award Made Possible by the Linda and Mike Mussallem Foundation MOUNTAIN VIEW, Calif.-(BUSINESS WIRE)-Nominations open April 2 for the 2026 Thomas J. Fogarty Innovation Prize (Fogarty Prize), a prestigious recognition honoring an innovator or team that has developed and brought to market a life-changing medical technology. The award includes an unrestricted $100,000 cash prize, a custom-cast bronze medal, and a black-tie celebratory dinner and award ceremony that brings together leaders from across the medtech industry. "The Fogarty Prize and gala celebrate the innovators, mentors, and visionaries who make this industry extraordinary," said Andrew Cleeland, CEO of Fogarty Innovation. "What we do matters. We improve, restore, and sometimes save the lives of millions." Share This marks the second year of the award, which is named in honor of cardiovascular surgeon and serial medical technology innovator Thomas J. Fogarty, MD. His inventions transformed surgical practice, and his relentless pursuit of "a better way" continues to inspire generations of innovators. Fogarty passed away in December 2025. The inaugural Fogarty Prize was awarded to Allan Zingeler, Raju Viswanathan, PhD, and Michael Mahoney of Boston Scientific for the FARAPULSE(TM) PFA Platform, an advanced treatment for atrial fibrillation (AF), the most common sustained cardiac arrhythmia. The award was presented at a sold-out gala attended by more than 350 leaders from industry, venture, academia, healthcare, and local government. The Fogarty Prize was established through a founding grant from the Linda and Mike Mussallem Foundation. "The Thomas J. Fogarty Innovation Prize celebrates the boldness, creativity, and perseverance that define great innovators - qualities that Tom embodied every day," said Mike Mussallem, co-founder of the Linda and Mike Mussallem Foundation and former CEO and Chairman of the Board of Edwards Lifesciences. "Tom believed that, with the right innovation, medicine could always do better for patients, and he lived that conviction with integrity, generosity, and unwavering drive. This prize honors his remarkable legacy and his lifelong mission to empower others to challenge convention and solve healthcare's toughest problems." The Prize highlights the journey from idea to impact, recognizing the collaboration, persistence, and multidisciplinary effort required to drive a new therapy to patients and achieve broad acceptance and use. It also brings the medtech community together to celebrate breakthrough ideas and the shared mission of improving patient care. "The Prize and gala celebrate the innovators, mentors, and visionaries who make this industry extraordinary," said Andrew Cleeland, CEO of Fogarty Innovation, the nonprofit educational medtech incubator founded by Fogarty that administers the Prize. "What we do matters. We improve, restore, and sometimes save the lives of millions around the world." Eligibility and Dates The Fogarty Prize recognizes a singular, clinically impactful technology. Nominees should embody the core values that define Dr. Fogarty's legacy - relentless curiosity, bold vision, technical excellence, and a deep commitment to improving human health. Recipients must be individuals (up to three per award). Nominations open April 2, 2026, and close July 31, 2026. The nomination form is available on the Fogarty Innovation website. Dr. Fogarty's Impact on Medical Innovation During his acclaimed career, Fogarty acquired 190 medical patents, including the Fogarty Balloon Embolectomy Catheter, the Hancock Tissue Heart Valve, and the AneuRx Endovascular Aortic Stent Graft. He founded or co-founded more than 45 medical technology companies and was honored by numerous organizations for his contributions to medical science, including induction into the National Inventors Hall of Fame and receipt of the Presidential Medal of Technology and Innovation. Recognizing that developing new medical technologies and bringing them to patients was "damn hard," Fogarty founded Fogarty Innovation in 2007 on the campus of El Camino Health to mentor the next generation of innovators and create an environment of camaraderie, education, and support. The organization has been led by Cleeland since 2017. About Fogarty Innovation Fogarty Innovation is a nonprofit educational medtech incubator dedicated to advancing human health worldwide. The organization's seasoned team helps companies navigate the path to commercialization, delivers practical educational programming to stakeholders across the ecosystem, and forges alliances that accelerate the invention, development, and deployment of new medical technologies into clinical care. Founded by Thomas J. Fogarty, MD, a world-renowned cardiovascular surgeon, inventor, and entrepreneur, Fogarty Innovation is headquartered on the campus of El Camino Health in Mountain View, California. Learn more: www.fogartyinnovation.org. About the Linda and Mike Mussallem Foundation After decades of philanthropic commitments, Linda and Mike officially unveiled the Linda and Mike Mussallem Foundation in 2024. The Foundation aims to harness the power of innovation and integrative health solutions to address complex healthcare challenges and create meaningful, long-lasting change for overlooked populations in need. Learn more: www.mussallemfoundation.org. More News From Fogarty Innovation MOUNTAIN VIEW, Calif.-( BUSINESS WIRE )-FARAPULSE team wins inaugural Thomas J. Fogarty Innovation Prize for transformative AFib therapy at SF gala celebration with medtech community... MOUNTAIN VIEW, Calif.-( BUSINESS WIRE )-Finalists for the inaugural Fogarty Prize are therapies that have transformed the treatment of cancer, atrial fibrillation and serious birth defects... MOUNTAIN VIEW, Calif.-( BUSINESS WIRE )-Thomas J. Fogarty Prize launches to recognize high-impact medtech innovations... Fogarty Innovation. Release Summary Nominations open April 2 for the 2026 Fogarty Prize, a $100,000 award honoring an innovator or team behind a life-changing medical technology Release Versions
Boston Scientific has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, whilst Emerson Collective joined as a new backer. The pre-revenue startup is developing "Mathematical Superintelligence", focusing on advanced reasoning that eliminates AI hallucinations by requiring outputs in Lean4 programming language for verification. Its Aristotle model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, the company has raised $295 million across three rounds in 14 months. It currently offers Aristotle via free API and targets commercialisation in safety-critical sectors like aerospace and finance.